Price and Volume Movers
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announced that the FDA has approved its Biologics License Application (BLA) for SILIQ (brodalumab) injection, for subcutaneous use, in patients with moderate-to-severe plaque psoriasis. As expected, a black box warning for the risks in patients with a history of suicidal thoughts or behaviour was included. Shares of the company closed down 3.8% to $16.22.
Neuralstem, Inc. (Nasdaq:CUR) provided an update today regarding its Phase 2 clinical trial of NSI-189 for the treatment of major depressive disorder (MDD). Enrollment of the final patient has been completed and data are now due in 3Q 2017. Shares spiked to over $4 in early trading before settling down to close up 19% to $3.77.
Evoke Pharma (NASDAQ: EVOK) announced the pricing of its public offering of 2.41m common shares priced at $2.90 per share. Shares closed down 12% to $2.99.
Other major price movers:
X T L Biopharmaceuticals Ltd (NASDAQ:XTLB): $3.88; +19%.
Crispr Therapeutics AG (NASDAQ:CRSP): $18.49; +16%.
Peregrine Pharmaceuticals (NASDAQ:PPHM): $0.443; +15%.
ContraFect Corp (NASDAQ:CFRX): $2.00; +14%.
Albireo Pharma, Inc. (NASDAQ:ALBO): $22.59; +11%
Anavex Life Sciences Corp (NASDAQ:AVXL): $5.44; -12%.
Genocea Biosciences Inc (NASDAQ:GNCA): $4.44; -10%.
OHR Pharmaceutical Inc (NASDAQ:OHRP): $0.95; -10%.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN): $4.27; -9%.
Moleculin Biotech Inc (NASDAQ:MBRX): $1.21; -9%.
Full pipeline updates: